Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

gy development effort and favorable

preclinical research results showing that 2ME2 has disease modifying or

"DMARD" activity, The FDA has accepted EntreMed's IND for 2ME2 in RA,

which included an extensive human safety dossier in 300 patients from

the oncology studies. Panzem(R) for RA represents a safe, orally

administered, small molecule alternative to current biologicals and a

potential "first-in-class" cross-over opportunity from oncology. The

Company plans to initiate a normal volunteer clinical trial in 2008

and seek a development partner to manage larger multi-arm Phase 2 and

Phase 3 studies.

EntreMed President & CEO, James S. Burns, commented, "We are concentrating our resources on fewer programs that we believe have greater potential for product registration and ultimately commercialization. We have three promising oncology programs to pursue in 2008: MKC-1 in multiple Phase 1 and 2 trials, ENMD-1198 that we expect to enter into Phase 2 before year end, and ENMD-2076 that will begin a Phase 1b clinical trial shortly, together with our initial clinical trial for Panzem(R) in a potentially larger RA market."

Mr. Burns further commented, "Our goal in 2008 is to continue moving ahead on priority programs while maintaining our cash expenditures at approximately the same level as in 2007. As part of our financial plan, we are also focusing increased attention on partnering one or more of our programs in order to fund and advance our programs into later stages of development. We will, however, continue to selectively seek opportunities such as individual products or companies that could favorably impact the quality of our pipeline, allow us to de-risk the Company, and enhance shareholder value."

A digital recording of the Company's will be available approximately two hours after the completion of the conference and will be accessible for 60 days. To access the rec
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Breakthrough in monitoring tropical deforestation announced in Copenhagen 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2Old hay and Alpine ibex horns reveal how grasslands respond to climate change 2Old hay and Alpine ibex horns reveal how grasslands respond to climate change 3Researchers prolong the half life of biopharmaceutical proteins 9974 1Researchers prolong the half life of biopharmaceutical proteins 9974 2New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 1New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 2New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 3New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 4New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 5New Poll Shows Values Voters in Lockstep on the 26amp 3B 238216 3BMoral Implications 26apos 3B of Health Care Reform 57646 6The Childrens Hospital of Philadelphia Celebrates a Successful Finish to its Hope Lives Here Fundraising Campaign 57644 1The Childrens Hospital of Philadelphia Celebrates a Successful Finish to its Hope Lives Here Fundraising Campaign 57644 2The Childrens Hospital of Philadelphia Celebrates a Successful Finish to its Hope Lives Here Fundraising Campaign 57644 3The Childrens Hospital of Philadelphia Celebrates a Successful Finish to its Hope Lives Here Fundraising Campaign 57644 4The Childrens Hospital of Philadelphia Celebrates a Successful Finish to its Hope Lives Here Fundraising Campaign 57644 5